Improving Outcomes in Metastatic HER2+ Breast Cancer: Translating Evidence to Clinical Practice

Experts in oncology center discussion on patient scenarios and share insight on the treatment landscape for patients with HER2+ metastatic breast cancer.

EP. 1: Landscape of HER2+ Metastatic Breast Cancer: Patient Overview

May 15th 2023

Expert oncologist Kevin Kalinsky, MD, MS, reviews a patient case of HER2+ metastatic breast cancer and highlights key findings in this disease setting.

EP. 2: HER2+ Metastatic Breast Cancer: An Evolving Treatment Armamentarium

May 15th 2023

Comprehensive insight on the treatment armamentarium currently available to patients with HER2+ metastatic breast cancer and CNS disease.

EP. 3: HER2+ Metastatic Breast Cancer: Factors in Selecting 2L Therapy and Beyond

May 22nd 2023

A key opinion leader in HER2+ metastatic breast cancer shares his perspective on key factors in selecting second or later-line therapy.

EP. 4: Role of T-DXd in Patients With HER2+ Metastatic Breast Cancer and CNS Metastasis

May 22nd 2023

A brief discussion on the role of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who progress on tucatinib therapy.

EP. 5: HER2+ Breast Cancer With CNS or Leptomeningeal Metastases: Future Directions in Care

May 29th 2023

Closing out his review of therapy for HER2+ metastatic breast cancer, Kevin Kalinsky, MD, MS, looks toward future evolutions in the treatment landscape.

EP. 6: Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

June 5th 2023

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

EP. 7: Overview of the HER2+ Metastatic Breast Cancer Treatment Armamentarium

June 5th 2023

A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.

EP. 8: Factors in Selecting Third-Line Therapy for HER2+ Metastatic Breast Cancer

June 12th 2023

Focused discussion on factors that help inform treatment selection for patients with HER2+ metastatic breast cancer in the third-line setting.

EP. 9: Role of Brain Metastases and Quality of Life in Treatment Decisionmaking

June 12th 2023

Virginia Kaklamani, MD, DSc, shares her perspective on the roles that brain metastases and quality of life play, respectively, in selecting treatment for HER2+ mBC.

EP. 10: Addressing Resistance to HER2-Targeted Therapy in Metastatic Breast Cancer

June 19th 2023

Comprehensive insight on acquired resistance to HER2-targeted therapy in metastatic breast cancer, and how treatments can be selected and sequenced thereafter.